Spectrum Pharmaceuticals has today announced the promotion of Joseph Turgeon to President and Chief Operating Officer. Mr. Turgeon was previously Senior Vice President and Chief Commercial Officer. Spectrum also announced the promotion of Thomas Riga to Senior Vice President, Chief Commercial Officer. Mr. Riga was previously Vice President, Corporate Accounts.

“We are fortunate to have an experienced, passionate, and inspiring leader like Joe Turgeon spearhead the company,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “Joe was responsible for building a top sales organization and for launching four of the world’s top-selling biologicals, during his over two decades at Amgen. With a rare depth of experience in the biotechnology industry, a keen understanding of our business, and very strong leadership skills, Joe is uniquely qualified for this position. He has been instrumental in helping Spectrum execute our strategy since he joined us in 2012. With multiple launches and NDAs planned in the coming years, I believe Joe’s leadership is exactly what Spectrum needs to become a leader in hematology/oncology.”

“I take up this new role with honor, humility, and confidence,” said Joseph Turgeon, President and Chief Operating Officer. “We have an exciting year ahead of us, with several meaningful milestones. Our base business remains strong, and could be further strengthened with the potential FDA approval of Beleodaq ™ later this year. The ongoing proof-of-concept study SPI-2012 has the potential to take Spectrum to the next level. I am committed to improving lives of patients, to improving prospects for our shareholders, and to bringing out the best in our team.”

Joseph Turgeon joined Spectrum in October 2012 and brings over 30 years of pharmaceutical sales experience, including various executive leadership roles at Amgen. Prior to joining the Company, he spent 22 years at Amgen Inc. as Vice President, Sales, where he built and led the sales organization across multiple areas, including oncology, inflammation, and bone health. Mr. Turgeon was responsible for launching most of the drugs at Amgen. At Spectrum, he has built a world-class sales organization that has increased efficiency and visibility. He was also instrumental in the launch of Marqibo® (vinCRIStine sulfate LIPOSOME injection) last year in a record time of about 7 weeks. Mr. Turgeon holds a B.S. from Jacksonville University, where he studied microbiology and economics.

Thomas Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly, and Dendreon. Since joining Spectrum, Mr. Riga has been instrumental in the reorganization of the Corporate Accounts function, and in successful partnership and renegotiation with various partners. He has co-led the Commercial contracting strategy and attracted some of the industry’s top talent to join Spectrum.

Ken Keller resigned as Executive Vice President, Chief Operating Officer of the company to pursue other opportunities.

“I would like to personally thank Ken for his contributions to the company,” added Dr. Shrotriya. “On behalf of the team at Spectrum, I wish him the best in his future endeavors.”